Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended in a multimodal pain management to reduce pain intensity and to spare opioid use. However, there is a controversy in its use in pleurodesis surgery as it could block the process of pleurodesis in surgical pneumothorax. In addition, NSAIDs could increase the risk of pneumothorax recurrence.
The investigators hypothesized that NSAIDs are safe during pleurodesis with a better pain management without increasing the risk of pneumothorax reccurence.

Start Date01 Feb 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire Amiens-Picardie

[+2]

ChiCTR2400094325

/ SuspendedPhase 4IIT

Effect of Ketoprofen Cataplasms on Relief Pain in Patients with Osteoarthritis:a Randomized Controlled clinical Trial

Start Date30 Dec 2024

Sponsor / Collaborator

Affiliated Zhongshan Hospital of Dalian University

ChiCTR2400093878

/ SuspendedPhase 4IIT

Clinical study of ketoprofen gel paste for pain relief after minimally invasive arthroscopic surgery for knee osteoarthritis: a randomized controlled trial

Start Date16 Dec 2024

Sponsor / Collaborator-

100 Clinical Results associated with Ketoprofen

100 Translational Medicine associated with Ketoprofen

100 Patents (Medical) associated with Ketoprofen

11,357

Literatures (Medical) associated with Ketoprofen

01 Apr 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Using artificial neural networks to elucidate retention interactions on stationary phases with amine moieties dedicated to supercritical fluid chromatography

Author: Plachka, Katerina ; Gazarkova, Tatana ; Pilarova, Veronika ; Plachká, Kateřina ; Nováková, Lucie ; Pilařová, Veronika ; Svec, Frantisek ; Švec, František ; Garrigues, Jean-Christophe ; Novakova, Lucie ; Gazárková, Taťána

The retention mechanisms of small mols. on a wide range of stationary phases using different mobile phase compositions are one of the most discussed topics in current state-of-the-art supercritical fluid chromatog. (SFC).Although various theories have been published on retention behavior, prediction, and stability over time, an in-depth insight into the mechanisms is still lacking.Our study focused on the description of the retention mechanisms on columns with amine moieties, i.e., 2-ethylpyridine, 2-picolylamine, 1-aminoanthracene, and diethylamine, dedicated to SFC, using three different compositions of organic modifier, i.e., methanol, methanol + 10 mmol/L NH₃, and methanol + 2% H₂O, in CO₂.An extensive set of analytes characterized by more than 200 mol. descriptors was used.The importance of the effect of each mol. descriptor on the retention behavior was determined by artificial neural networks.Thus, the descriptors increasing and/or decreasing retention on individual columns using different mobile phase compositions were defined.The data collected over one year of column use were statistically evaluated to describe the retention behavior of small mols. on the tested stationary phases using three organic modifiers and to describe the changes in retention behavior over time.As the development of the SFC method can be laborious and time-consuming, this publication offers a detailed description of the interactions taking place between the analyte and the SFC stationary phase.Understanding these fundamental processes will enable faster development of SFC methods using quality-by-design principles.

01 Mar 2025·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Unveiling the potential of pullulan in enhancing ketoprofen release from PHBV filaments

Article

Author: Medeiros, Simone F ; Vieira, Thiago A ; Mulinari, Daniella R ; de Carvalho, Layde T ; Maia, Lana S ; Rosa, Derval S ; Tada, Dayane B ; de Macedo, Erenilda Ferreira ; da Silva, Maryana B

In this study, sustainable poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) and pullulan (PUL)/PHBV filaments were prepared with ketoprofen for scaffold preparation. The research aimed evaluate the influence of pullulan in the filament properties, such as thermal, morphological, and biological behavior. Hansen parameters demonstrated the difference in the miscibility of the polymers and drug in the blend. This difference in solubility contributed to thermal stabilization, and reduced the crystallinity of the blend, observing a reduction in crystalline peak at 30.82° (002). The morphology change was observed by SEM images, in which ketoprofen appears to smooth and homogenize the filament surface. Cytotoxicity tests on osteoblast cells confirmed that all samples were biocompatible, and the presence of ketoprofen was comparable to the control group. Importantly, the in vitro release of ketoprofen revealed that the presence of pullulan increased the cumulative release of ketoprofen, from 0.1 % to 36 %, within 240 min of the dissolution test. This highlights the crucial role of pullulan in fine-tuning drug release. These findings underscore the potential of these materials for bone regeneration applications, combining the cytotoxic and cell adhesion properties of PHBV with the osteoblasts, and offering precise control over the degradation process and drug release through the incorporation of pullulan.

01 Mar 2025·ENVIRONMENTAL RESEARCH

Pilot-scale adsorption of pharmaceuticals from municipal wastewater effluent using low-cost magnetite-pine bark: Regeneration/enumeration of viable bacteria with a study on their biotoxicity

Article

Author: Risteelä, Sofia ; Mohammadzadeh, Mahdiyeh ; Brandt, Kristian Koefoed ; Bello, Adedayo ; Lassen, Simon Bo ; Leiviskä, Tiina

A low-cost and renewable magnetite-pine bark (MPB) sorbent was evaluated in continuous-flow systems for the removal of various pharmaceuticals from municipal wastewater effluent following membrane bioreactor (MBR) treatment. A 33-day small-scale column test (bed volume: 791 cm³) was conducted using duplicate columns of biochar (BC, Novocarbo) and activated carbon (AC, ColorSorb) as reference for two columns of BC and MPB in order to compare the efficiency of AC and MPB. After the small-scale column test, the pharmaceutical concentrations were generally below the detection limit. In the next stage, a four-month pilot-scale adsorption test was performed using a large column (bed volume: 21 L) filled with BC and MPB. A variety of compounds were removed after the pilot-scale column, including trimethoprim (99.7%), hydrochlorothiazide (81.8%), candesartan (26.0%), carbamazepine (86.1%), ketoprofen (89.4%), clindamycin (86.6%), oxazepam (91.3%), sulfadiazine (38.6%), sulfamethoxazole (58.3%), tramadol (88.9%), zopiclone (73.5%), venlafaxine (93.7%), furosemide (93.5%), fexofenadine (91.6%) and losartan (81.2%). The enumeration of viable bacteria in the pilot-scale column samples revealed that regenerating the BC-MPB bed with NaOH increased bacterial counts in the treated water due to the desorption of adsorbed bacteria from the bed. A biotoxicity study using the Nitrosomonas europaea bioreporter strain indicated that the wastewater was generally non-toxic to this nitrifying bacterium and regeneration of pilot-scale column samples caused short-time toxicity immediately after regeneration. The study confirms that MPB is efficient for the adsorption of pharmaceuticals and can be applied in column mode with a support material such as BC. Therefore, MPB is a viable alternative for AC for the remediation of pharmaceutical-contaminated wastewaters.

News (Medical) associated with Ketoprofen

27 Jun 2023

·m.economictimes.com

CORONA remedies buys Sanofi India's ortho brand Myoril

Ahmedabad-based pharmaceutical company CORONA Remedies has acquired the muscle relaxant brand Myoril from Sanofi India for Rs234 crore. The acquisition includes Myoril and its extensions. This acquisition comes after Corona's previous acquisitions of drug brands from GlaxoSmithKline and Abbott India. Myoril, with annual sales of Rs38 crore and a growth rate of 6.8%, will strengthen Corona's presence in the growing muscle relaxant market in India, which is valued at Rs1,626 crore. Ahmedabad-based pharmaceutical company CORONA Remedies has acquired leading muscle relaxant brand Myoril from Sanofi India, for Rs234 crore. Corona has acquired Myoril (Thiocolchicoside) and its extensions such as Myoril Plus (Ketoprofen + Thiocolchicoside), said people aware of the development. Another domestic pharmaceutical majors Torrent Pharma and Eris Lifesciences were also in the race to acquire these orthopaedic brands, said sources. When contacted, a Sanofi spokesperson confirmed the development. The acquisition of the Myoril brand for the Indian market is effective from June 28, 2023, added the spokesperson. Corona Remedies is backed by domestic PE fund ChrysCapital which owns about 30% stake with an investment of about Rs670 crore ($90 million). In 2017, Corona had acquired four drug brands of GlaxoSmithKline - Dilo-BM, Dilo-DX, Stelbid and Vitneurin. Two brands from Abbott India - Obimet and Thyrocab range of products (for diabetes and hyperthyroidism) were also acquired in 2018. The muscle relaxant market in India is valued at Rs. 1,626 crore and it is growing at 13%. Myoril has annual sales of Rs. 38 crore and a growth of 6.8%, according to IQVIA May 2023 data. Sanofi India has been divesting its non-core products as part of concentrating on its core areas such as chronic diseases. As part of the transformation, Sanofi India changed its organisation structure from eight Business Units (BUs) to a focused group of three BUs - Diabetes; Consumer Healthcare; and Transplants & Cardiology, said the company's annual report. Earlier, Sanofi India had sold its nutraceutical portfolio consisting of 16 brands and 30 stock-keeping units (SKUs) to a consortium of Universal Medicare-Kedaara Capital for Rs587 crore in 2021. In the same year, Sanofi India had sold its skin care brands - Soframycin and Sofradex brands to Encube Ehticals for a total consideration of Rs 125 crore. In May, Sanofi India demerged its consumer healthcare business to a wholly owned subsidiary Sanofi Consumer Healthcare India as a value-driven move to accelerate growth for both the pharmaceuticals business and consumer healthcare business in India. There are interest from Indian pharma companies for a few of Sanofi's consumer brands such as DePURA and Combiflam, added sources. The Indian pharmaceutical industry has been growing at an average of 10% over the past five years. In 2022, the industry grew by 6.5%, adding nearly Rs12,000 crore of incremental sales. The demand for acute therapies increased, while most chronic therapies like diabetes and cardiovascular treatments remained relatively steady, said the Sanofi India report. The IQVIA Prognosis Report (2022) projects that the Indian pharmaceuticals market is expected to grow at a CAGR 9.2% between 2021-26 and reach a market size of Rs2,95,100 crore by 2026. The rapid expansion of the e-pharmacy sector, expansion of co-marketing agreements, coupled with the introduction of new OTC regulations will also be a growth driver till 2026.

AcquisitionDrug Approval

17 Apr 2023

·www.drugs.com

Get Pain Relief With the Most Common Arthritis Medications

MONDAY, April 17, 2023 -- Arthritis is a common disease that causes pain and inflammation in different body joints, making it difficult to enjoy everyday tasks and physical activity. Fortunately, there are many different medications for arthritis. Depending on what type of arthritis you have and its severity, an arthritis medication may help you manage pain and other symptoms. Here is a breakdown of the most common arthritis medications, how they work and their potential side effects. The Arthritis Foundation lists the following as the medications used to treat arthritis: Analgesics including acetaminophen (Tylenol) and opioids Nonsteroidal anti-inflammatory drugs (NSAIDs) Corticosteroids Disease-modifying antirheumatic drugs (DMARDs) including biologics and targeted DMARDs Analgesics The Arthritis Foundation reports that analgesics may help with mild to moderate pain, but they will not help with the inflammation associated with arthritis. Analgesics work in the nervous system and alter how your brain perceives pain. They can be used to treat the pain associated with any type of arthritis, although more effective options are available. Analgesics can be opioid, non-opioid or a combination. Common analgesics are: Acetaminophen (Tylenol) Codeine Oxycodone Fentanyl Hydrocodone Potential side effects: Kidney damage Liver damage Addiction Constipation Gastrointestinal bleeding Use caution when taking these medications; take only as prescribed. NSAIDs NSAIDs work by blocking prostaglandin. According to the Cleveland Clinic , one role prostaglandins play is forming clots and causing inflammation at the site of an injury. NSAIDs are used to treat the pain and inflammation associated with rheumatoid arthritis and osteoarthritis . Common over-the-counter (OTC) NSAIDs are: Aspirin (Bayer, St. Joseph, Anacin, Excedrin and more) Ibuprofen (Motrin, Advil) Naproxen sodium (Aleve) Prescription NSAIDs are: Celecoxib (Celebrex) Diclofenac (Voltaren, available by brand name in topical form) Fenoprofen (Nalfon) Indomethacin (Indocin, available by brand name in liquid form) Ketorolac tromethamine (Toradol) Meclofenamate sodium (Meclomen) Diflunisal (Dolobid) Tolmetin (Tolectin) Ketoprofen (Orudis) Flurbiprofen (Ansaid) Potential side effects of NSAIDs are: Increased risk of stomach and bowel issues like ulcers and bleeding Increased risk of stroke Heart problems Stomach pain Nausea Diarrhea/constipation Corticosteroids According to the Arthritis Foundation , corticosteroids mimic cortisol, a hormone your body produces naturally. They are used to treat inflammatory types of arthritis, including rheumatoid arthritis and psoriatic arthritis. They are great for short-term relief of inflammation but are not recommended for long-term use because of their side effects. Your doctor may prescribe a lower dose if you require them for long-term use. Common corticosteroids: Prednisone (Deltasone, Prednicot, Cotolone) Prednisolone (Orapred, Omnipred) Cortisone (Cortone) Hydrocortisone (Cortef, Hydrocort) Triamcinolone (Aristocort) Dexamethasone (Decadron) Common side effects of corticosteroids: Blood sugar spikes Weight gain Bone loss Risk of cataracts High blood pressure Infections Mood changes DMARDs The Arthritis Foundation says that DMARDs work with the body to “stop or slow the disease process in inflammatory forms of arthritis.” They work by blocking inflammation. There are many different DMARDs on the market, and they all have different ways of working in the body. Conventional DMARDs work by broadly suppressing the immune system. Often they are used in combination with other therapies. Targeted DMARDs block specific pathways inside immune cells. Biologic DMARDs are produced by live cells and work on specific immune proteins called cytokines. Common DMARDs: Apremilast (Otezla) Baricitinib (Olumiant) Cyclophosphamide (Cytoxan) Cyclosporine (Gengraf, Neoral) Hydroxychloroquine (Plaquenil) Leflunomide (Arava) Methotrexate (Otrexup, Rasuvo, RediTrex) Mycophenolate mofetil (CellCept) Sulfasalazine (Azulfidine) Tofacitinib (Xeljanz, Xeljanz XR) According to the Cleveland Clinic , common side effects of traditional DMARDs include: Loss of appetite Nausea Diarrhea Abdominal pain Rash, allergic reaction Liver problem Increased risk of infection Low blood cell counts Common side effects of biologic DMARDs include: Increased risk of common and serious infections Reactivation of tuberculosis, herpes zoster, and hepatitis B and C Increased cholesterol levels, increased liver enzymes and low blood cell counts Increased risk of clotting When prescribed DMARDs, inform your doctor of any other medications, including over-the-counter medicines, you are taking to avoid drug interactions. Some of these medications can cause teratogenicity (defects in a developing fetus.) Writing recently in the Journal of the American Academy of Physician Assistants (JAAPA ), physician assistant Michelle DiBiase and Dr. Samantha Kohn remind people that "The mainstay of pharmacologic therapy is early intervention with use of nonbiologic and biologic DMARDs together with adjunctive medications such as NSAIDs, oral and intra-articular corticosteroids, and analgesic medications, including opioids." Your primary care provider or rheumatologist will work closely with you to determine which medications are best for your treatment. It is vital to keep them apprised of any side effects and let them know if the treatment is ineffective. They can work with you to find a treatment that helps relieve the pain and inflammation caused by arthritis. Posted April 2023

Drug Approval

10 Nov 2008

·www.biospace.com

Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group Comprehensive Investor Relations and Media Outreach to Commence

LA JOLLA, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. ( ) (the "Company"), a specialty pharmaceutical company focused on developing and commercializing non-invasive, topically administered medications, has retained the Investor Relations Group ("IRG"), a thirteen-year-old, highly recognized corporate communications firm based in New York City, to serve as its investor relations and public relations firm. IRG will strive to increase the Company's public exposure and to communicate the advantages of its innovative proprietary transdermal delivery technology, Transdel(TM), its lead topical drug, Ketotransdel(TM) and its other drug candidates through a focused campaign. On the investor relations front, IRG will use its proprietary database of investors to introduce the Company to targeted members of the investment community through pre-qualified one-on-one introductions, e-mails to professionals that have opted-in to receive communication, interviews, and traditional outreach. In the public relations arena, IRG will educate audiences of editors, writers, and segment producers of local and national trade and consumer print, radio, on-line, and broadcast media outlets about the Company and its role in the market. The Company's lead topical drug, Ketotransdel(TM), utilizes their Transdel(TM) cream formulation to facilitate the passage of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin barrier to reach targeted underlying tissue where the drug exerts its prolonged localized anti-inflammatory and analgesic effect. The Company is also investigating other novel and generic drugs and promising therapeutic areas in combination with using their patented transdermal delivery system. Furthermore, the Company is actively pursuing the development of cosmeceutical products. "With our lead product, Ketotransdel(TM), in Phase 3 clinical trial, and a strong pipeline of co-development opportunities utilizing our Transdel(TM) platform technology, this is an opportune time to increase our visibility within the investment and media community," said Dr. Juliet Singh, President and CEO of Transdel Pharmaceuticals. "As we remain focused on our clinical program and growth objectives, we look forward to IRG communicating our progress to the appropriate target audiences." About Transdel Pharmaceuticals, Inc. Transdel Pharmaceuticals, Inc. is a specialty pharmaceutical company developing non-invasive, topically-delivered medications. The Company's innovative patented proprietary Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of drugs through the tough skin barrier to reach the target underlying tissues. In the case of Ketotransdel(TM), the Transdel(TM) cream allows the active ingredient ketoprofen to reach the target soft tissue and exert its well-known anti-inflammatory and analgesic effects. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel(TM) platform technology for products in pain management and other therapeutic areas. For more information, please visit About The Investor Relations Group, Inc. The Investor Relations Group, Inc. (IRG) offers a full-service corporate communications program designed to suit the many unique needs of public companies. The program utilizes a proprietary, targeted approach to reach institutional investors, analysts, and the media-at-large. For further information, please visit the company's website at Safe Harbor Statement The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. CONTACT: John Lomoro, CFO of Transdel Pharmaceuticals, Inc., +1-858-457-5300, johnl@transdelpharma.com; or Investor Relations, Rachel Colgate or Michael Crawford, or Media Relations, Laura Colontrelle or Janet Vasquez, all of Investor Relations Group, Inc., +1-212-825-3210 Web site:

Financial StatementGeneric Drug

100 Deals associated with Ketoprofen

External Link

KEGG	Wiki	ATC	Drug Bank
D00132	Ketoprofen	M02AA10 M01AE03	DB01009

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Periarthritis	JP	Hisamitsu Pharmaceutical Co., Inc.	06 Aug 2007
Tendinopathy	JP	Hisamitsu Pharmaceutical Co., Inc.	06 Aug 2007
Tumescence	JP	Hisamitsu Pharmaceutical Co., Inc.	01 Sep 1989
Analgesia	JP	Kissei Pharmaceutical Co., Ltd.	29 Nov 1986
Inflammation	JP	Kissei Pharmaceutical Co., Ltd.	29 Nov 1986
Osteoarthritis	US	Wyeth-Ayerst Laboratories	09 Jan 1986
Pain	US	Wyeth-Ayerst Laboratories	09 Jan 1986
Rheumatoid Arthritis	US	Wyeth-Ayerst Laboratories	09 Jan 1986
Arthritis	CN	Mudanjiang Lingtai Pharmaceutical Co. Ltd.	01 Jan 1986

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ankle Injuries	Phase 3	US	Hisamitsu Pharmaceutical Co., Inc.	01 Apr 2008
Shoulder Pain	Phase 3	US	Hisamitsu Pharmaceutical Co., Inc.	01 Apr 2008
Osteoarthritis, Knee	Phase 3	US	Hisamitsu Pharmaceutical Co., Inc.	01 Sep 2007
Acute migraine	Phase 2	US	Achelios Therapeutics, Inc.	01 Mar 2014
Temporomandibular Joint Disorders	Phase 2	-	Achelios Therapeutics, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EULAR2022	Not Applicable	Non-radiographic axial spondyloarthritis	43	Continuous NSAIDs intake	izubynsvah(zpvceskxxn) = tseoktdvwj tslyluvlqw (klfwfcxtxz ) View more	Positive	01 Jun 2022
				Occasional NSAIDs intake	tpvneosxus(lodlmmiwbx) = bhlpeplpke sbwghmcnhv (gkrfbvapto )
WCO_IOF_ESCEO2020	Not Applicable	Osteoarthritis, Knee First line	23	Ketoprofen applications	ooizuatbvi(rnwfqrwnky) = qbufwltzgc jcerbqxtkh (utlefdlsps ) View more	Positive	20 Aug 2020
NCT02568644 (CTgov)	Not Applicable	Migraine Disorders	60	Extract of ginger+Intravenous ketoprofen (Extract of Ginger)	zrauixhsmp(oxsxoojnig) = ztomzjvcmj ybpcduskhs (aejvoyivcl, ayyiwsrfdy - lgfujskevd) View more	-	07 Apr 2020
				Cellulose+Intravenous ketoprofen (Cellulose)	zrauixhsmp(oxsxoojnig) = zbudxizbia ybpcduskhs (aejvoyivcl, yvkzmjvhpp - msbgieicoq) View more
NCT01893879 (PCTTPL, CTgov)	Not Applicable	Solid tumor \| Lymphedema	14	laboratory biomarker analysis+(RS)2-(3-benzoylphenyl)-propionic acid ((RS)2-(3-benzoylphenyl)-Propionic Acid)	aqyvwxanyc(okvejoioyc) = vqqxyajwof jjpwmnruco (zigexzjdiq, orupliwvas - bjopjbktsj) View more	-	18 May 2017
				placebo for study drug (Placebo for Study Drug)	aqyvwxanyc(okvejoioyc) = rfejbpwnsg jjpwmnruco (zigexzjdiq, fnzvtfkfad - jeqjdtvfbo) View more
NCT02099006 (Topicals, CTgov)	Phase 2/3	Pain \| Genital Diseases, Female	9	Baclofen+Amitriptyline+ketoprofen+Loperamide+Ketamine+Gabapentin (Medications)	smeucjllxn(sopeygifem) = unakjnqtxx hbrdmfqrpd (xhsmredreo, zktmkjrroi - cvwnptwmsc) View more	-	15 Jul 2016
				placebo (Placebo)	smeucjllxn(sopeygifem) = ynnrrdxwch hbrdmfqrpd (xhsmredreo, qxsibyvcps - rsxxyzifpl) View more
NCT00553605 (NAP, CTgov)	Phase 4	Renal Colic	340	Parecoxib (Parecoxib)	crhkvqpmmh(kymxjonbzg) = dohrctooyz kgppshgdaz (yawmlvuzyl, zoxxdktkja - mubpqkjwwk) View more	-	28 Jan 2013
				Ketoprofen (Ketoprofen)	crhkvqpmmh(kymxjonbzg) = tdtycpyrgn kgppshgdaz (yawmlvuzyl, avzwmnkxui - gxaiejsrzn) View more
DIRACTIN (EULAR2009)	Not Applicable	Osteoarthritis, Knee	-	Diractin® 100 mg ketoprofen	ktgdqfbrum(semgurznib) = epsyoiquoq leorrkkket (eewoozmlzt ) View more	Positive	10 Jun 2009
				Placebo	ktgdqfbrum(semgurznib) = vfgjdpkezu leorrkkket (eewoozmlzt ) View more
EULAR2007	Phase 3	Osteoarthritis, Knee	866	Placebo	qfrvqlfjjf(koizsrxotw) = The majority of treatment related adverse events (AE) were dermal AE including erythema (8.6% with 100mg, 8.1% with 50mg, 3.6% with 25 mg ketoprofen and 4.5% with placebo). Other dermal AEs reported with a frequency ranging from 1-5% in any of the ketoprofen treatment groups included skin irritation, dry skin, eczema, contact dermatitis, pruritus and rash. Other AEs had an incidence rate below 1%. fflunhdzqu (hcmfshtlgn )	Positive	13 Jun 2007
				25 mg ketoprofen in IDEA-033
EULAR2006	Not Applicable	Osteoarthritis, Knee	397	IDEA-033 (Ketoprofen in Transfersome® Gel)	pjpivnbuoy(pxntxybtet) = Overall, 53.6% of subjects treated with IDEA-033, 50.0% of subjects treated with celecoxib, and 48.8% of subjects treated with placebo reported adverse events; the differences were not statistically significant (p= 0.7116) rohhzcoxzd (iwsxmkmysg )	Positive	21 Jun 2006
				Celecoxib
SFN2001	Not Applicable	Myalgia	-	Peroral ketoprofen 50 mg	ziffykjnln(fkogdwxosx) = hklnbbgjpf lodiymcyum (ofswjidsmg )	-	15 Nov 2001
				Peroral ketoprofen 100 mg	ziffykjnln(fkogdwxosx) = xorabufohk lodiymcyum (ofswjidsmg )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ketoprofen

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation